ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 9 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 18 miu/ml - solution for injection - interferon alfa-2b - chronic hepatitis b, chronic hepatitis c, hairy cell leukemia, chronic myelogenous leukemia, aids related kaposi`s sarcoma, malignant melanoma.treatment of metastatic or recurrent renal cell carcinoma non hodgkin`s lymphoma. treatment of high tumour burden follicular lymphoma as adjunct to apropriate combination induction chemotherapy such as a chop like regimen.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 80 mcg / 0.5 ml - powder for solution for injection - interferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 10 miu - solution for injection - interferon alfa-2b - - chronic hepatitis b. - chronic hepatitis c. - hairy cell leukaemia. - chronic myelogenous leukaemia. - multiple myeloma. - folicular lymphoma. - carcinoid tumour. - malignant melanoma.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 100 mcg / 0.5 ml - powder for solution for injection - peginterferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

ישראל - עברית - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 120 mcg / 0.5 ml - powder for solution for injection - peginterferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

ישראל - עברית - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

ישראל - עברית - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).